Biotech | January 22, 2022
Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
UCB plans to submit regulatory applications in Q3 2022
UCB plans to submit regulatory applications in Q3 2022
Biocon has reported consolidated financial results for the period ended December 31, 2021
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
Ram’s appointment follows the launch of the CDI India division in October 2021.
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
It provides Covid-19 detection and Omicron surveillance in less than two hours
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Narayanan to lead SeQuent through next phase of consolidation and growth
Subscribe To Our Newsletter & Stay Updated
